At Vivreon Biosciences
We are developing a new class of small molecule therapeutics for the treatment of chronic inflammatory diseases. Our candidate therapies defend healthy tissue by targeting a previously untapped inflammatory pathway – selective blockade of the calcium release-activated calcium (CRAC) channel.
Chronic inflammation damages healthy tissue in ulcerative colitis, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.
Ulcerative Colitis (UC) affects over 1 million people in the Unites States, with these numbers increasing every year. UC is a chronic inflammatory disease affecting the gastrointestinal (GI) tract, resulting in ulcers of the colon and rectum. A large proportion of patients do not respond to current therapies, and there is considerable need to develop improved therapies for UC patients. Vivreon Biosciences is developing an alternative approach to completely and specifically suppress chronic inflammation by targeting the CRAC channel.
Alzheimer's disease (AD) affects over 5.5 million people in the United States, and 1 out of every 10 people over age 65 has AD. AD causes substantial degeneration of healthy brain tissue, resulting in memory loss and disability. Neuroinflammation is an important contributor to AD disease progression, and ongoing neuroinflammation can be visualized in the brains of persons suffering from AD. Brain cells called microglia are the source of inflammation in AD, and mutations in microglia increase the risk of developing AD.
Parkinson's disease (PD) is a degenerative brain disease and affects approximately 1 million people in the United States. PD is a progressive disease, beginning as small tremors before advancing into problems with balance and a slowing of movement. There are currently no drugs available to slow this progression. In PD, brain microglial cells are constantly exposed to α synuclein protein and exist in a state of chronic inflammation.
Vivreon protects healthy tissue by an entirely new mechanism compared to currently available therapies. In animal models of disease, our therapeutics are effective, safe, taken orally, and act specifically at sites of chronic inflammation. We are currently refining our lead compounds with the goal of submitting an Investigational New Drug application with the Food and Drug Administration.
6990 Carrol Road, Suite A, San Diego, CA 92121
Omed Muzaffery, M.B.A., M.S.
Mr. Muzaffery is a co-founder and the Chief Financial Officer of Vivreon Biosciences. Mr. Muzaffery holds an M.B.A. from the University of Southern California Marshall School of Business, an M.S. in Material Science and Engineering...
Andrew C. Newman, Ph.D.
Dr. Newman is a co-founder and the Chief Operating Officer of Vivreon Biosciences. Dr. Newman leads research and partnership efforts, ensuring that Vivreon’s commercial value is realized...
Contact us for more information on treatment of chronic inflammatory diseases.
VV3000 Series: Neuroprotection
VV4000 Series: Neuroprotection
John T. Ransom, Ph.D.
Dr. Ransom is a co-founder and the Chief Scientific Officer of Vivreon Biosciences, where he leads Vivreon's drug development programs. Dr. Ransom has previously served in CSO and VP positions at multiple...
Milton L. Greenberg, Ph.D.
Dr. Greenberg is a co-founder and the President of Vivreon Biosciences, where his passion is to solve unmet needs in chronic diseases. Dr. Greenberg is an Assistant Professor at the University of California, Irvine...
Oral Immune Therapeutics